BioSpace News Archive

Harrow announced the launch of its patent-pending, next-generation compounded Atropine formulations, which are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx.

Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with nab-paclitaxel and gemcitabine for treatment of patients with locally advanced pancreatic cancer.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the fourth quarter and full year ended December 31, 2022 after the market close on Tuesday, February 28, 2023.

Ocean Biomedical, a next-generation biopharma company, announced the completion of its business combination with Aesther Healthcare Acquisition Corp., a publicly traded special purpose acquisition company.

Xilis and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to deploy Xilis’s proprietary MicroOrganoSphere™ (MOS) technology in support of preclinical research to accelerate the development of novel cancer therapies.

TAE Life Sciences (TLS) today announced that the first accelerator-based BNCT (AB-BNCT) clinical research center at Xiamen Humanity Hospital (XHH) has now treated 12 patients in its Investigator Initiated Trial (IIT) aimed at evaluating the safety and efficacy of BNCT in the treatment of advanced refractory malignant tumors.

Hillstream BioPharma, Inc. announced that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange.

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced positive final results from a Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, being studied for the treatment of BK viremia (BKV) in adult kidney transplant recipients.

T2 Biosystems, Inc. announced the pricing of its previously announced underwritten public offering of 11,111,111 shares of common stock and warrants to purchase up to 22,222,222 shares of common stock at a combined public offering price of $1.08 per share of common stock and accompanying warrants, for initial gross proceeds of approximately $12 million, before underwriting discounts and commissions and offering expenses.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has gained rights to ARO-PNPLA3, formerly called JNJ-75220795, which was part of a 2018 research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.